Combination therapy of alpha-glucosidase inhibitor and a sulfonylurea compound prolongs the duration of good glycemic control

Metabolism: Clinical and Experimental

Volumn 51, Issue 12, 2002, Pages 1548-1552

  Matsumoto, Kazunari ^a   Sera, Yasunori ^a   Abe, Yasuyo ^a   Tominaga, Tan ^a   Ueki, Yukitaka ^a   Miyake, Seibei ^a  

^a SASEBO CHUO HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; GLIBENCLAMIDE; GLICLAZIDE; GLUCOSE; HEMOGLOBIN A1C; SULFONYLUREA DERIVATIVE; VOGLIBOSE;

ACUTE HEART INFARCTION; ADULT; ARTICLE; BIOASSAY; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DRUG FATALITY; FEMALE; FOLLOW UP; GENERAL CONDITION DETERIORATION; HUMAN; HYPERGLYCEMIA; JAPAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; STROKE; SURVIVAL; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0036908143     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1053/meta.2002.36310     Document Type: Article

References (22)

1. Robertson P, Klein D: Treatment of diabetes mellitus. Diabetologia 35:S8-S17, 1992 (suppl)
2. UKPDS Group: Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998
3. Borissova A, Koev D, Minev M, et al: Factors for development of secondary failure to sulfonylurea drugs in non-insulin-dependent diabetes mellitus. Acta Diabetol Lat 28:91-98, 1991
4. Birkeland K, Rishaug U, Hanssen K, et al: NIDDM: A rapid progressive disease. Results from a long term, randomized, comparative study of insulin or sulphonylurea treatment. Diabetologia 39:1629-1633, 1996
5. Leahy JL: Impaired β-cell function with chronic hyperglycemia: "Overworked β-cell" hypothesis. Diabetes Rev 4:298-319, 1996
6. Sako Y, Grill V: Coupling of β-cell desensitization by hyperglycemia to excessive stimulation and circulating insulin in glucose-infused rats. Diabetes 39:1580-1583, 1990
7. Hillebrand I: Pharmacological modification of digestion and absorption. Diabet Med 4:147-150, 1987
8. Kingma P, Menheere P, Sels J, et al: α-Glucosidase inhibition by miglitol in NIDDM patients. Diabetes Care 15:478-483, 1992
9. Coniff R, Shapiro J, Robbins D, et al: Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. Diabetes Care 18:817-824, 1995
10. Matsumoto K, Yano M, Miyake S, et al: Effects of voglibose on glycemic excursions, insulin secretion, and insulin sensitivity in non-insulin-treated NIDDM patients. Diabetes Care 21:256-260, 1998
11. Matsumoto K, Yano M, Ueki Y, et al: Protection of the pancreatic β-cells by an α-glucosidase inhibitor. Diabetes Care 21:1206-1207, 1998
12. World Health Organization: Diabetes Mellitus: Report of a WHO Study Group. Tech Rep Ser No. 727. Geneva, Switzerland, World Health Organization, 1985
13. Rossetti L, Giaccari A, DeFronzo RA: Glucose toxicity. Diabetes Care 18:1156-1159, 1990
14. Matsumoto K, Akazawa S, Abiru N, et al: Insulin response after treatment depends on fasting plasma glucose level in NIDDM. Diabet Res Clin Pract 26:129-135, 1994
15. Johnston P, Coniff R, Hoogwerf B, et al: Effects of the carbohydrase inhibitor miglitol in sulfonylurea treated NIDDM patients. Diabetes Care 17:20-29, 1994
16. Coniff R, Shapiro J, Seaton T, et al: Multicenter, placebo-controlled trial comparing acarbose (BAYg 5421) with placebo, tolbutamide, and tolbutamide plus acarbose in non-insulin-dependent diabetes mellitus. Am J Med 98:443-451, 1995
17. Bayraktar M, Van Thiel D, Adalar N: A comparison of acarbose versus metformin as an adjuvant therapy in sulfonylurea-treated NIDDM patients. Diabetes Care 19:252-254, 1996
18. Lam K, Tiu S, Tsang M, et al: Acarbose in NIDDM patients with poor control on conventional oral agents. Diabetes Care 21:1154-1158, 1998
19. Holman R, Cull C, Turner R, et al: A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (UKPDS 44). Diabetes Care 22:960-964, 1999
20. Matsumoto K, Miyake S, Yano M, et al: Glucose tolerance, insulin secretion, and insulin sensitivity in nonobese and obese Japanese subjects. Diabetes Care 20:1562-1568, 1997
21. Taniguchi A, Nakai Y, Fukushima M, et al: Pathogenic factors responsible for glucose intolerance in patients with NIDDM. Diabetes 41:1540-1546, 1992
22. Taniguchi A, Nakai Y, Doi K, et al: Glucose effectiveness in two subtypes within impaired glucose tolerance: A minimal model analysis. Diabetes 43:1211-1217, 1994